

# Instem PLC

07:43 15 Nov 2019

## Instem makes earnings-enhancing US\$4.6mIn US acquisition

Instem PLC (LON:INS) is moving into safety assessment software with a US\$4.6mIn, earnings-enhancing US acquisition.

It is buying Leadscope, which has developed a suite of products that use sophisticated artificial intelligence and machine-learning algorithms to predict potentially harmful drug side effects.

Users either subscribe to the various platforms or access them on a one-off, pay-per-use basis.

Instem is handing over a mix of cash and shares for the Columbus, Ohio-based firm, with US\$3.35mIn paid on the deal's completion. This will be followed by a deferred US\$750,000 and a US\$500,000 "earn-out".

### Informatics growth

The acquisition builds on the firm's small but rapidly growing informatics operation.

Informatics is a natural extension for Instem, whose software is used by pharma companies making drug submissions.

By processing and storing data it has garnered, the company has been able to develop gene- or drug-specific target safety assessments (TSAs).

TSAs are used to assess unintended adverse consequences of potential treatments before expensive investment is made and, crucially, long before they are administered to people. In other words, it helps identify the 'failures' early.

Currently, this process is costly, particularly for small and mid-sized firms, which have to outsource it.

### In silico approach

Instem's 'in silico' (computer-based) methodology is cheaper than the traditional, lab-based approach and brings with it an element of standardisation lacking currently.

"We run a technology-enabled service where we deliver a report on the safety of a gene," Gordon Smith Baxter, Instem's chief scientific officer told Proactive recently.

Instem's chief executive Phil Reason said Leadscope "aligns perfectly" with its strategy of expanding organically and acquisitively into "adjacent market areas".

"We have been in regular dialogue with Glenn [Myatt, CEO of Leadscope] and the team for over 10 years, looking for the right opportunity and timing to partner or acquire," Reason explained.

**Price:** 534

**Market Cap:** £89.04 m

### 1 Year Share Price Graph



### Share Information

**Code:** INS

**Listing:** AIM

<b>52 week</b>	<b>High</b>	<b>Low</b>
	<b>540</b>	<b>290</b>

**Sector:** Software & services

**Website:** [www.instem-iss.com](http://www.instem-iss.com)

### Company Synopsis:

*We help our over 500 international clients efficiently access, capture, analyze, report and submit high quality regulatory data, while maintaining compliance for their products around the world. This is combined with our unique ability to generate new knowledge through the extraction and harmonization of public and proprietary sources of actionable scientific information.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

"They have built a deep relationship with the regulatory authorities, a fantastic client base and a profitable recurring revenue stream. We are looking forward to delivering the next stage of growth across the enlarged business and helping our clients to achieve a material reduction in the time taken to bring their life-changing products to market."

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).